| Market Capitalization (Millions $) |
39 |
| Shares
Outstanding (Millions) |
38 |
| Employees |
8 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-50 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Annovis Bio Inc. is a biopharmaceutical company that was founded in 2008 and has its headquarters in Berwyn, Pennsylvania. The company focuses on developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and other related disorders.
Annovis Bio Inc. utilizes an integrated platform technology to identify and develop small molecule drugs that can address the root causes of neurodegenerative diseases. The company's approach involves targeting multiple pathologies of these disorders, including protein misfolding, inflammation, oxidative stress, and impaired energy metabolism.
The company has developed two lead compounds, ANVS-401 and ANVS-411, which are designed to address critical targets in neurodegenerative diseases. ANVS-401 is a phosphodiesterase type 7 (PDE7) inhibitor that prevents the breakdown of cyclic adenosine monophosphate (cAMP), a molecule that plays an essential role in neuronal function. ANVS-411 is an inhibitor of both 11e-hydroxysteroid dehydrogenase type 1 (11e-HSD1) and 15-lipoxygenase (15-LO), enzymes that are involved in neuroinflammation and oxidative stress in the central nervous system.
Annovis Bio Inc. is also developing a diagnostic test called ANSnap, which is designed to detect early-stage neurodegeneration by measuring levels of toxic proteins in cerebrospinal fluid (CSF). This test has the potential to identify patients who are at risk of developing neurodegenerative diseases before significant damage to their brains has occurred.
Annovis Bio Inc. has collaborations with leading academic institutions, including the University of Pennsylvania, Thomas Jefferson University, and Harvard Medical School. The company has also received funding from the National Institutes of Health (NIH) and the Alzheimer's Drug Discovery Foundation (ADDF).
In summary, Annovis Bio Inc. is a biopharmaceutical company that focuses on developing novel therapies for neurodegenerative diseases. The company's integrated platform technology allows it to target multiple pathologies of these disorders. Annovis Bio Inc. has developed two lead compounds, ANVS-401 and ANVS-411, and is also developing a diagnostic test called ANSnap. The company has collaborations with leading academic institutions and has received funding from the NIH and ADDF.
Company Address: 101 Lindenwood Drive, Suite 225 Malvern 19355 PA
Company Phone Number: 875-3192 Stock Exchange / Ticker: NYSE ANVS
|
0.25%